Effect of eurecline and butylphthalein for patients with acute cerebral infarction
Objective To analyze the effects of eurecline and butylphthalein on cognitive function,vascular endothelial function,and daily living ability in patients with acute cerebral infarction.Methods A total of 100 patients with acute cerebral infarction treated in Bayannur City Hospital from March 2021 to March 2023 were selected for the randomized controlled trial,and were divided into an observation group and a control group by lottery,with 50 cases in each group.There were 24 males and 26 females in the control group;they were(60.17±8.92)years old.There were 27 males and 23 females in the control group;they were(59.45±8.42)years old.The control group took intravenous infusion of eurekline.The observation group took eurecline and butylphthalein.The clinical efficacies,cerebral blood flow parameters[plasma viscosity,whole blood viscosity,fibrinogen(FIB)],vascular endothelial function[vascular endothelial growth factor(VEGF),endothelin-1(ET-1),and nitric oxide(NO)],and scores of Montreal Cognitive Assessment Scale(MoCA)and Modified Barthel Index(MB1)before and after the treatment,and incidences of adverse reactions were compared between the two groups.The independent-sample t test,paired t test,and X2 test were used.Results The total effective rate of the observation group was significantly higher than that of the control group[92.00％(46/50)vs.76.00％(38/50)],with a statistical difference(x2=4.962;P=0.029).After the treatment,the plasma viscosity,whole blood viscosity,and level of FIB in the observation group were lower than those in the control group[(1.74±0.52)mPa·s vs.(2.05± 0.60)mPa·s,(16.59±6.33)mPa·s vs.(21.37±6.54)mPa·s,and(2.34±0.78)g/L vs.(2.93±0.72)g/L],with statistical differences(t=2.761,3.714,and 3.930;all P＜0.05).After the treatment,the levels of ET-1,NO,and VEGF in the observation group were better than those in the control group[(48.53± 5.49)ng/L vs.(54.61±6.52)ng/L,(45.54±6.80)μmol/L vs.(38.22±5.71)μmol/L,and(54.21± 8.35)ng/L vs.(49.64±6.08)ng/L],with statistical differences(t=5.044,5.829,and 3.129;all P＜0.05).After the treatment,the scores of MBI,MoCA,and NIHSS in the observation group were better than those in the control group[(68.37±12.54)vs.(55.91±11.47),(24.67±3.21)vs.(21.13±3.95),and(7.65±1.13)vs.(10.21±1.84)],with statistical differences(t=5.184,4.918,and 8.383;all P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group[14.00％(7/50)vs.10.00％(5/50);x2=0.379,P=0.538].Conclusion Eurecline combined with butylphthalein for patients with acute cerebral infarction can significantly improve the therapeutic effect and their cerebral microcirculation and vascular endothelial function and promote their recovery of cognitive function and daily living ability,and has high safety,so it is worthy of clinical promotion.
Cerebral infarctionEureclineButylphthaleinCognitive functionVascular endothelial functionDaily living ability
万方数据
维普
